Cannabis psychosis is a state in which marijuana use triggers hallucinations, delusions, or severely disorganized thinking that goes beyond the ordinary “high.” In clinical terms, it sits on a spectrum: mild perceptual distortions during intoxication can, once they reach a certain severity and persist long enough, cross the diagnostic threshold into what the DSM-5 calls Cannabis-Induced Psychotic Disorder.1PubMed Central. Cannabis and Psychosis Through the Lens of DSM-5 The condition is not just a bad trip that fades in hours. For a meaningful fraction of people who experience it, cannabis psychosis marks the beginning of a longer psychiatric story, and the details of that story depend on genetics, the potency of the product, the age at which use begins, and whether the person keeps using.
What It Looks and Feels Like
The core features of cannabis psychosis overlap with psychosis from any cause. A person may hear voices, see things that are not there, or develop beliefs with no basis in reality, such as being watched, tracked, or controlled. Thought patterns can become fragmented: sentences trail off, ideas connect in ways that make sense only to the person speaking, or the person withdraws entirely and stops responding. In the emergency department, people presenting with cannabis-related psychosis are more likely to be acutely agitated, and one study found that a positive THC screen predicted a higher likelihood of needing physical restraint and injectable sedation compared to psychosis presentations without THC involvement.2Psychiatry Research. Cannabis use among patients presenting to the emergency department for psychosis: Associations with restraint use, medication administration, psychiatric hospitalization, and repeat visits
Clinicians have documented cases in which cannabis psychosis produces symptoms that closely mimic the so-called first-rank symptoms of schizophrenia: the feeling that thoughts are being inserted into or withdrawn from your mind, or that an outside force controls your body.3PubMed Central. Cannabis-induced psychosis masquerading schizophrenia or vice-versa? A diagnostic dilemma That overlap is what makes diagnosis tricky, but it also signals how seriously the brain can be affected. A person in the middle of an episode typically has no insight into what is happening. They do not recognize that their perceptions are distorted, which is part of why emergency presentations can be volatile.
Potency, Frequency, and Age
Not all cannabis carries the same risk. The THC concentration of what a person uses matters enormously. In a London case-control study, 78% of people presenting with a first episode of psychosis had been using high-potency cannabis (the kind commonly called “skunk”), compared with 37% of matched controls. The odds ratio for psychosis among high-potency users was roughly seven times that of non-users.4PubMed Central. High-potency cannabis and the risk of psychosis That same study found daily use carried about a sixfold increase in risk, and using for more than five years roughly doubled it. A recent European review confirmed this pattern across multiple countries, linking products above 15–25% THC to elevated risk of psychosis, anxiety, panic symptoms, and episodes of derealization.5PubMed Central. Mental health consequences of contemporary cannabis use in Europe: potency, patterns of use, and health system context A scoping review of adolescents and young adults echoed this, concluding that high-potency products are more strongly tied to psychosis and cognitive problems than lower-potency alternatives.6PubMed Central. Influence of cannabis potency on mental health outcomes among adolescents and young adults: scoping review
Age at first use adds another layer of risk. The adolescent brain is still wiring itself, and THC acts on receptors that are especially abundant during that developmental window. A large study of adolescents in northern California, where typical flower THC content exceeds 20%, found that past-year cannabis use was associated with roughly double the risk of developing a psychotic disorder by age 26.7JAMA Health Forum. Adolescent Cannabis Use and Risk of Psychotic, Bipolar, Depressive, and Anxiety Disorders That association appeared even when defining use broadly as any use in the past year, not just daily or heavy use. Multiple longitudinal studies have now established that regular cannabis use in adolescence and young adulthood predicts a higher risk of psychotic symptoms later in life.8PubMed Central. Cannabis use and the risk of developing a psychotic disorder
Genetics and Individual Vulnerability
Most people who use cannabis, even frequently, never develop psychosis. The difference between those who do and those who do not appears to be partly genetic. Research into gene-environment interaction suggests that multiple gene variants, rather than any single one, combine with environmental stressors like cannabis exposure and psychological stress to raise a person’s risk.9PubMed Central. Gene-environment interplay between cannabis and psychosis
A systematic review of genetic studies found the most consistent signal in a gene called COMT, which helps regulate dopamine. Carrying a particular version of that gene was associated with higher susceptibility to cannabis-induced psychosis. A gene called AKT1, which is indirectly involved in dopamine signaling, showed a similar pattern for a specific genotype. Intriguingly, the only genome-wide association study in the review flagged a signal near a cholinergic receptor gene rather than any dopamine target, hinting that the biology is more complex than the standard dopamine-centric explanation.10Pharmacological Research. Cannabis induced psychosis: A systematic review on the role of genetic polymorphisms
The relationship between genetics and cannabis use runs in both directions. A study using genetic risk scores found that people with a higher inherited predisposition to schizophrenia were more likely to use cannabis and to use it in larger amounts. That does not erase the possibility that cannabis independently increases psychosis risk, but it does mean that part of the statistical association between cannabis and schizophrenia reflects people prone to psychosis gravitating toward the drug.11PubMed Central. Genetic predisposition to schizophrenia associated with increased use of cannabis
How Doctors Tell It Apart from Schizophrenia
Separating cannabis psychosis from the onset of schizophrenia is one of the hardest problems in psychiatry. Both can feature hallucinations, paranoia, and disorganized thought. Both can arrive in the same age window, the late teens and early twenties. The clinical features overlap so much that case reports describe the two conditions as “masquerading” as each other.3PubMed Central. Cannabis-induced psychosis masquerading schizophrenia or vice-versa? A diagnostic dilemma The key diagnostic clue is timing: cannabis-induced psychotic disorder should resolve once the drug clears the body. If symptoms persist for weeks after the person stops using, clinicians start considering a primary psychotic disorder. But because heavy users may have cannabinoids stored in body fat for extended periods, even this timeline can be blurry.
The diagnostic framework in the DSM-5 treats cannabis intoxication, cannabis-induced psychotic disorder, and schizophrenia as points along something approaching a continuum. Intoxication with mild perceptual changes sits at one end; a lasting schizophrenia diagnosis sits at the other. The uncomfortable truth is that for some people, the episode that starts as cannabis-induced psychosis eventually earns a schizophrenia diagnosis.1PubMed Central. Cannabis and Psychosis Through the Lens of DSM-5
The Transition to Long-Term Psychotic Illness
This is the statistic that makes cannabis psychosis more than a transient concern. A meta-analysis of follow-up studies found that about 20% of people diagnosed with cannabis-induced psychosis later received a schizophrenia spectrum diagnosis, and about 5% were later diagnosed with bipolar disorder.12PubMed Central. Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis A randomized controlled trial tracking people with substance-induced psychotic disorders found that those whose psychosis was linked to cannabis had the highest transition rate to schizophrenia of any substance group, at about 38%, with an adjusted odds ratio of roughly 2.4 compared to non-users.13PubMed Central. Transition rates to schizophrenia and early intervention effectiveness in substance-induced and brief psychotic disorders: a randomized controlled trial
Those numbers vary across studies depending on how long people were followed and how the initial episode was defined. But the direction is consistent: cannabis-induced psychosis carries a real and substantial risk of evolving into a chronic psychotic disorder, and that risk appears higher than for psychosis triggered by most other substances.
Treatment During an Acute Episode
In the emergency setting, the immediate goal is safety and stabilization. Mild cannabis-related psychosis sometimes resolves with supportive care alone. One published case report described a patient whose psychosis, along with low potassium levels and an abnormal heart rhythm, resolved over two days with minimal intervention beyond observation and supportive treatment.14PubMed Central. Psychiatric and medical management of marijuana intoxication in the emergency department More severe presentations typically require antipsychotic medication and sometimes benzodiazepines for acute agitation.
In a real-world clinical study of hospitalized cannabis psychosis patients, nearly all received antipsychotics, with risperidone being the most frequently prescribed at a mean dose of about 8 mg per day. About a third also received benzodiazepines alongside their antipsychotic, and a quarter were on a combination of antipsychotics, antidepressants, and benzodiazepines. Antipsychotic monotherapy was relatively uncommon, used in fewer than one in five patients.15PubMed Central. Real world clinical outcomes of treatment of cannabis-induced psychosis and prevalence of cannabis-related primary psychosis: a retrospective study
Preventing Relapse After Recovery
Once the acute episode has resolved, the question shifts to keeping psychosis from coming back. Two large-scale studies have examined which antipsychotic medications work best for relapse prevention specifically after cannabis-induced psychosis. Long-acting injectable formulations of aripiprazole and olanzapine showed the strongest protection, roughly cutting relapse risk by 70% or more. Clozapine and oral aripiprazole also reduced the risk meaningfully. Quetiapine, by contrast, showed no significant benefit for preventing relapse in this population.16PubMed Central. Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis 17Psychiatry Research. Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study Long-acting injectables may be especially helpful because they remove the daily decision to take a pill, which matters in a population that may have mixed feelings about ongoing treatment.
Stopping cannabis use is its own form of relapse prevention, and the data here is straightforward. A study tracking people in the first two years after psychosis onset found that those who had been regular cannabis users before the episode but quit afterward had the most favorable course of illness regarding relapse.18The Lancet Psychiatry. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study Specialized addiction treatment programs that combine motivational interviewing, cognitive behavioral therapy, family involvement, and case management have been designed and trialed for this exact situation: young people with both cannabis use and psychosis.19PubMed Central. The CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis Quitting is easier to recommend than to accomplish, though. Research on why some users manage to stop has found that experiencing psychotic-like symptoms is itself one of the strongest predictors of both quitting and wanting to quit, while people who continue using tend to emphasize the pleasurable effects.20PubMed Central. Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: a cannabis discontinuation hypothesis
What CBD Does and Does Not Do
THC is the component driving psychosis risk, but cannabis also contains cannabidiol, or CBD, which appears to push in the opposite direction. A narrative review of the available evidence found that CBD may reduce psychotic-like symptoms triggered by THC in healthy volunteers and ease positive symptoms in people with schizophrenia.21PubMed Central. Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review This is relevant to the real-world risk picture because the trend in commercial cannabis over the past two decades has been toward higher THC and lower CBD. A product that is 30% THC with negligible CBD delivers a very different pharmacological experience from a plant that was 5% THC and had a meaningful counterbalance of CBD. The shift toward high-potency, low-CBD products may explain part of why cannabis-related psychosis presentations have increased in places where they have been tracked.
What Happens to the Brain’s Own Cannabinoid System
Your body makes its own cannabis-like molecules, called endocannabinoids, that help regulate mood, stress responses, and perception. One of the most studied is anandamide. Research has found that people with psychosis who also use cannabis have lower circulating levels of anandamide compared to people with psychosis who do not use.22PubMed. Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis A study measuring anandamide in spinal fluid found something even more striking: people with schizophrenia who used cannabis infrequently had over ten times higher anandamide levels in their spinal fluid than those who used heavily. Frequent cannabis use appeared to suppress the brain’s own anandamide signaling in people with schizophrenia, but not in healthy people, and higher anandamide levels correlated with fewer symptoms.23Schizophrenia Research. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use
The implication is that the brain may produce anandamide as a kind of protective response during psychosis, and flooding the system with external THC could shut that protective mechanism down. This is still an area of active investigation, but it offers a plausible biological reason why cannabis use worsens outcomes for people already vulnerable to psychotic illness, beyond simply adding more THC to the mix.
Cannabis Legalization and Emergency Room Trends
The rollout of legal cannabis markets across North America has created a natural experiment. In Ontario, Canada, the opening of retail cannabis stores (the commercialization phase, as distinct from the earlier legalization-only phase) was associated with a 30% jump in emergency department visits for cannabis-induced psychosis, driven mainly by young adults aged 19–24 who were above the legal purchase age. Legalization alone, before stores opened, did not show the same spike.24PubMed. Association between non-medical cannabis legalization and emergency department visits for cannabis-induced psychosis In Colorado, youth psychosis hospitalizations involving cannabis use disorder rose from about 2 per 100,000 per month before policy changes to roughly 8.5 per 100,000 after recreational legalization, with a significant acceleration in the trend over time.25PubMed Central. Changes in psychosis-related emergency department and hospitalization rates among youth following cannabis legalization in Colorado
A broader analysis using insurance claims data across multiple U.S. states found that the opening of cannabis retail outlets was associated with more emergency department visits specifically among people who already had a psychosis diagnosis, with no corresponding increase among people without a history of psychosis.26PubMed Central. Emergency department use by individuals with and without psychosis after state-level cannabis legalization and commercialization That last finding is worth sitting with: commercialization did not appear to create a wave of new psychosis in the general population, but it did seem to worsen outcomes for people already living with psychotic illness. The pattern suggests that access and availability, rather than legality per se, are what change the risk landscape.
When Cannabis and Tobacco Overlap
Cannabis is rarely used in a vacuum, and what else a person uses matters. A study of people considered clinically at high risk for psychosis found that heavy cannabis use combined with light tobacco use was associated with nearly triple the risk of converting to a full psychotic disorder compared to using neither substance. The statistical signal was strong enough to be robust against unmeasured confounders.27PubMed Central. Cannabis and tobacco co-use predicts psychosis in clinical high risk cohorts The co-use pattern is common in practice, since many people mix cannabis and tobacco in joints, and the interaction appears to be more than additive. For clinicians screening young patients, asking about tobacco use alongside cannabis use may give a more complete picture of psychosis risk than asking about either alone.